Research Article
Antimicrobial Resistance Profile of Different Clinical Isolates against Third-Generation Cephalosporins
Table 4
Resistance pattern of the different clinical isolates to ceftazidime.
| Clinical isolates | Resistance pattern | Resistant | Intermediate | Susceptible | Total |
| E. coli | 41 (65.1%) | 10 (15.9%) | 12 (19.0%) | 63 | Citrobacter species | 29 (56.9%) | 8 (15.7%) | 14 (27.4%) | 51 | S. aureus | 16 (34.0%) | 20 (42.6%) | 11 (23.4%) | 47 | Enterobacter species | 35 (79.6%) | 6 (13.6%) | 3(6.8%) | 44 | K. pneumonia | 19 (73.1%) | 5 (19.2%) | 2 (7.7%) | 26 | K. oxytoca | 4 (80%) | 2 (20%) | 0 | 6 | Y. enterocolitica | 2 (33.3%) | 0 | 4 (66.7%) | 6 | Proteus species | 3 (60.0%) | 2 (40.0%) | 0 | 5 | Total | 149 (60.1%) | 53 (21.4%) | 46 (18.5%) | 248 (100) |
|
|